Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
The news feed for Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) captures the company’s transition as it integrates Decoy Therapeutics and pivots toward a peptide-conjugate antiviral and oncology platform. Press releases and regulatory announcements describe how Salarius, historically a clinical-stage biopharmaceutical company with oncology assets, completed a strategic merger with Decoy and is preparing to operate under the Decoy Therapeutics name and the Nasdaq ticker symbol DCOY.
Readers following SLRX news can expect updates on corporate transformation, including the planned and then confirmed changes to the corporate name and trading symbol, as well as details of the merger structure, preferred stock issuance and leadership changes documented in company communications and SEC filings. The news flow also highlights capital markets activity, such as underwritten public offerings of common stock and warrants, at-the-market issuances and efforts to regain and maintain compliance with Nasdaq listing standards, including reverse stock splits and panel monitoring.
Sector-specific coverage focuses on drug development and platform progress. Company announcements describe the IMP3ACT peptide-conjugate platform, pan‑coronavirus and broad-acting antiviral programs, and a peptide drug conjugate targeting GI cancers. News items also cover collaborations, notably with Texas Biomedical Research Institute for in vitro testing of peptide conjugate fusion inhibitors across influenza strains including H5N1 avian flu, and recognition from programs such as the Massachusetts Life Sciences Seed Fund, the Google AI startup program, the NVIDIA Inception program and BARDA’s BLUE KNIGHT initiative.
By monitoring this page, investors and observers can review historical and ongoing disclosures around SLRX’s oncology heritage, its integration with Decoy’s AI- and ML-enabled peptide-conjugate platform, financing transactions and interactions with the Nasdaq Capital Market, all drawn from company-issued news and related filings.
Salarius Pharmaceuticals (SLRX) will host a conference call on March 18, 2021, at 4:30 p.m. ET to discuss its Q4 2020 and full year 2020 financial results. The company, focused on developing treatments for pediatric cancers, has its lead candidate, seclidemstat, in a Phase 1/2 trial for Ewing sarcoma, having received several designations from the FDA aimed at expediting its development. The call details include U.S. and international dial-in numbers, with a webcast available on the company’s investor site.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced the closing of its public offering of 16,806,722 shares at $1.3685 per share, generating approximately $23 million in gross proceeds. This financing boosts Salarius' cash availability to around $37 million, sufficient to support ongoing clinical trials for its lead drug candidate, seclidemstat. The funding aims to enhance treatment for Ewing sarcoma and other cancers. Delivery of clinical trial data is anticipated in June 2021, presenting potential regulatory pathways and commercial opportunities.
Salarius Pharmaceuticals (SLRX) announced a public offering of 14,614,541 shares at $1.3685 each, aiming to raise approximately $20 million, with closing expected around March 8, 2021. The offering includes a 45-day option for underwriters to purchase an additional 2,192,181 shares. Ladenburg Thalmann is the book-running manager for this offering. The proceeds will support Salarius's clinical programs, including trials for its lead candidate, seclidemstat, a potential treatment for pediatric cancers and solid tumors.
Salarius Pharmaceuticals (Nasdaq: SLRX) has announced the commencement of an underwritten public offering of its common stock. The offering is subject to market conditions, and details regarding its size and terms remain undetermined. Ladenburg Thalmann & Co. Inc. is the sole book-running manager for this offering. The company has a registered shelf statement with the SEC, allowing for the sale of shares. Salarius focuses on developing new cancer therapies, particularly for pediatric and other challenging cancers, with its lead candidate currently undergoing clinical trials.
Salarius Pharmaceuticals (Nasdaq: SLRX) has initiated the expansion stage of its Phase 1/2 clinical trial for seclidemstat, targeting relapsed and refractory Ewing sarcoma patients. This phase includes two arms: combining seclidemstat with topotecan and cyclophosphamide for Ewing sarcoma, and using it as a single-agent therapy for Ewing-related sarcomas. Preliminary results show extended time to progression, with data readouts expected by the end of 2021 into 2022. The company aims to enhance treatment options for patients with limited alternatives.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Diamond Equity Research Emerging Growth Invitational Conference on February 24, 2021. The presentation will cover Salarius’ business overview, recent achievements, and upcoming clinical milestones for seclidemstat, a reversible LSD1 inhibitor currently in Phase 1/2 trials for Ewing sarcoma and advanced solid tumors. Attendees can participate in a Q&A session. A recording will be available post-event on the company’s investor page.
Salarius Pharmaceuticals has established the recommended Phase 2 dose (RP2D) for its seclidemstat in a Phase 1/2 trial focused on relapsed/refractory Ewing sarcoma. Data from the trial showcased a manageable safety profile and preliminary signs of drug activity, particularly in Ewing-related sarcoma patients. Encouraging results indicated over 75% tumor shrinkage in a refractory patient. The trial plans to expand to treat more patients and present full findings at a medical conference. Further data readouts are expected by the end of this year and early next year.
Salarius Pharmaceuticals announced its participation in the BIO CEO & Investor Digital Conference from February 16 to February 18, 2021. The company's management will engage in one-on-one virtual meetings with investors to discuss business developments and milestones related to seclidemstat, a reversible LSD1 inhibitor in clinical trials for Ewing sarcoma and advanced solid tumors. Salarius has received multiple FDA designations for seclidemstat and financial backing for its clinical programs, emphasizing its commitment to innovative cancer therapies.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The company focuses on developing innovative cancer therapies, particularly its lead candidate, seclidemstat, which is in clinical trials for pediatric cancers and advanced solid tumors. Salarius has received multiple designations from the FDA for seclidemstat and financial support from the National Pediatric Cancer Foundation and CPRIT to further its clinical programs.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that Dr. Daniela Y. Santiesteban will join the panel on Targeted Cancer Therapeutics at Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference, taking place January 19-21, 2021, virtually. The discussion will focus on the status and future of targeted cancer therapies. Salarius is advancing its lead candidate, seclidemstat, a reversible LSD1 inhibitor, currently undergoing clinical trials for Ewing sarcoma and advanced solid tumors. The company aims to establish maximum tolerated dose in its ongoing trials.